Cancer drug company G1 Therapeutics Inc. has added two new executives to its management team as it prepares its drugs for the market, according to a filing Thursday with the Securities and Exchange Commission.

The Research Triangle Park-based company, which raised $108 million in its initial public offering in May, hired Terry Murdock as senior vice president, development Operations, and Shannon Morris as as vice president, clinical development.

The hires are important as G1 Therapeutics is expecting Phase 2 trial data for one of its drugs and is expecting to launch a Phase 2 trial for its other drug.

“I’m excited to welcome Terry and Shannon to G1, and am confident their proven leadership and broad experience will help us maximize the potential of our oncology pipeline,” said Chief Executive Officer Mark Velleca in a statement.

Murdock most recently served as vice president and global head of the Oncology Center for Excellence at QuintilesIMS, also based in the Research Triangle Park.

Prior to his tenure with QuintilesIMS, Murdock held positions including President North America at Ergomed and senior vice president at Genzyme and Ilex Oncology, where he was responsible for the Phase 3 development, approval and launch of Campath in oncology and autoimmune indications.

Morris most recently served as senior clinical director of oncology at MedImmune.

Morris was a key contributor to the first biologics license application submission and the U.S. Food and Drug Administration approval of Imfinzi, an immunotherapy product for bladder cancer.

Previously, Morris held several leadership roles at GlaxoSmithKline, culminating in her position as senior clinical director.

G1 Therapeutics fell 47 cents to $12.53 on Thursday.